ClinicalTrials.gg
CompletedNCT02745080EXCEED 1Updated Jan 27, 2021Results posted

Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis

A Phase 3 interventional study of Secukinumab and Adalimumab in Psoriatic Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 156 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-27.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
853
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing secukinumab in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. secukinumab · Arthritis, Psoriatic.

Enrollment
2nd of 26
853 · median 231
Started
2017
the only one that year
Phase 3
16 of 26
1 open now
Registered
15th of 26
by date
Lead sponsor
17 of 26
Novartis Pharmaceuticals

Among the 26 studies testing secukinumab in Arthritis, Psoriatic, this one is the 2nd largest by enrollment, is the only one that started in 2017, is one of 16 in phase 3, and was the 15th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 26 studies testing secukinumab in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing secukinumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

This was a randomized, double-blind, active controlled, multicenter, parallel-group study evaluating secukinumab monotherapy and adalimumab monotherapy in approximately 850 patients with active psoriatic arthritis (PsA) who are naïve to biologic therapy and are intolerant or having inadequate response to conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs).

Read the detailed description

The total maximum study duration, including the screening period was up to 76 weeks.

At Baseline, patients whose eligibility was confirmed were randomized to 1 of 2 groups (1:1): Group 1 (secukinumab 300 mg) or Group 2 (adalimumab 40 mg).

In order to maintain the blind, both groups received 1 or 2 placebo s.c. injections to keep consistency in the number of injections at each dosing visit. Secukinumab (300 mg) was available in 2 x 1.0 mL pre-filled syringes (PFS) and adalimumab was available in 1 x 0.4 mL PFS. Placebo (1.0 and 0.5 mL PFS) was also available.

Secukinumab 300 mg s.c injection (2 x 1 mL PFS) was administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks to Week 48.

Adalimumab 40 mg (1 x 0.4 mL PFS) was administered at Baseline followed by dosing every 2 weeks until Week 50.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • Psoriatic Arthritis
  • secukinumab
  • adalimumab
  • monoclonal antibody
  • CASPAR
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of PsA classified by CASPAR
  • Rheumatoid factor and anti-CCP antibodies negative
  • Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of >= 2cm diameter or nail changes consistent with psoriasis or documented history of plaque psoriasis
  • Inadequate control of symptoms with NSAIDs
  • Inadequate control of symptoms with a conventional DMARD.

Key Exclusion Criteria:

  • Pregnant or nursing women
  • Evidence of ongoing infectious or malignant process
  • Previous exposure to any biologic drug for Psoriatic Arthritis or Psoriasis
  • Subjects taking high potency opioid analgesics
  • Ongoing use of prohibited psoriasis treatments/medications
  • Previous treatment with any cell-depleting therapies including but not limited to anti-CD20 agents.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
853 participants (actual)

Study arms

  • Experimental
    Secukinumab 300 mg s.c.

    Secukinumab 300 mg administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 48.

    Biological: Secukinumab

  • Active comparator
    Adalimumab 40 mg s.c.

    Adalimumab 40 mg administered at Baseline followed by dosing every 2 weeks until Week 50.

    Biological: Adalimumab

Interventions

  • BiologicalSecukinumab

    Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio

    Also known as: AIN457

  • BiologicalAdalimumab

    Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 52

    Clinical response, failure to permanently discontinue study medication prematurely, and lack of need for rescue medication was required for a patient to achieve treatment success. The primary endpoint is the proportion of patients with monotherapy ACR20 response at Week 52 where monotherapy ACR20 response is defined as meeting the following 3 conditions: 1. achieving American College of Rheumatology 20 (ACR20) response 2. no permanent study treatment (secukinumab or adalimumab) discontinuation before or at Week 50 (the last dosing visit) 3. no use of conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs) cDMARDs (including Methotrexate (MTX)) after Week 36 (regardless of the starting time of taking cDMARDs)

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 52

    The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score.

    Time frame: Week 52

  2. Percentage of Participants Who Achieved an American College of Rheumatology 50% (ACR50) Response at Week 52

    Clinical response, failure to permanently discontinue study medication prematurely, and lack of need for rescue medication was required for a patient to achieve treatment success. The secondary endpoint is the proportion of patients with monotherapy ACR50 response at Week 52 where monotherapy ACR50 response is defined as meeting the following 3 conditions: 1. achieving American College of Rheumatology 50 (ACR50) response 2. no permanent study treatment (secukinumab or adalimumab) discontinuation before or at Week 52 3. no use of conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs) cDMARDs (including Methotrexate (MTX)) after Week 36 (regardless of the starting time of taking cDMARDs)

    Time frame: Week 52

  3. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI Score) at Week 52

    The HAQ-DI assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, "are you able to..." perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 52

  4. Percentage of Participants Who Achieved Resolution of Enthesitis at Week 52

    Enthesitis refers to inflammation of entheses, the site where ligaments or tendons insert into the bones. Resolution was defined as the absence of recorded enthesitis; conducted by the study assessor.

    Time frame: Week 52

07

Results

Posted Jan 27, 2021

Participant flow

This study was conducted at 161 centers in 26 countries worldwide: Australia, Bulgaria, Canada, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Israel, Italy, South Korea, Latvia, Lithuania, The Netherlands, Poland, Portugal, Russia, Slovakia, Spain, UK and USA.

Participant flow — Overall Study
MilestoneSecukinumab 300 mg s.c.Adalimumab 40 mg s.c.
Started426427
Completed371338
Not completed5589
Withdrew: Adverse event1321
Withdrew: Lack of efficacy1123
Withdrew: Lost to follow-up33
Withdrew: Physician decision30
Withdrew: Protocol violation31
Withdrew: Withdrawal by subject2241

Outcome measures

PrimaryPercentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 52

Clinical response, failure to permanently discontinue study medication prematurely, and lack of need for rescue medication was required for a patient to achieve treatment success. The primary endpoint is the proportion of patients with monotherapy ACR20 response at Week 52 where monotherapy ACR20 response is defined as meeting the following 3 conditions: 1. achieving American College of Rheumatology 20 (ACR20) response 2. no permanent study treatment (secukinumab or adalimumab) discontinuation before or at Week 50 (the last dosing visit) 3. no use of conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs) cDMARDs (including Methotrexate (MTX)) after Week 36 (regardless of the starting time of taking cDMARDs)

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 52
Percentage of ParticipantsSecukinumab 300 mg s.c.Adalimumab 40 mg s.c.
Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 5267.4 (62.8 to 71.7)61.5 (56.8 to 66.0)
Statistical analysis
  • Secukinumab 300 mg s.c. vs Adalimumab 40 mg s.c. · Regression, Logistic · p = 0.0719 · Odds ratio (or): 1.30 · 95% CI 0.98 to 1.72Odds ratio, 95% confidence interval, and p-value are from a logistic regression model with treatment as a factor and baseline weight as a covariate
SecondaryPercentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 52

The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score.

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 52
Percentage of ParticipantsSecukinumab 300 mg s.c.Adalimumab 40 mg s.c.
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 5265.4 (58.8 to 71.5)43.2 (36.5 to 50.2)
Statistical analysis
  • Secukinumab 300 mg s.c. vs Adalimumab 40 mg s.c. · Regression, Logistic · p = <0.0001 · Odds ratio (or): 2.49 · 95% CI 1.67 to 3.71Odds ratio, 95% confidence interval, and p-value are from a logistic regression model with treatment as a factor and baseline weight as a covariate
SecondaryPercentage of Participants Who Achieved an American College of Rheumatology 50% (ACR50) Response at Week 52

Clinical response, failure to permanently discontinue study medication prematurely, and lack of need for rescue medication was required for a patient to achieve treatment success. The secondary endpoint is the proportion of patients with monotherapy ACR50 response at Week 52 where monotherapy ACR50 response is defined as meeting the following 3 conditions: 1. achieving American College of Rheumatology 50 (ACR50) response 2. no permanent study treatment (secukinumab or adalimumab) discontinuation before or at Week 52 3. no use of conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs) cDMARDs (including Methotrexate (MTX)) after Week 36 (regardless of the starting time of taking cDMARDs)

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved an American College of Rheumatology 50% (ACR50) Response at Week 52
Percentage of ParticipantsSecukinumab 300 mg s.c.Adalimumab 40 mg s.c.
Percentage of Participants Who Achieved an American College of Rheumatology 50% (ACR50) Response at Week 5249.0 (44.3 to 53.7)44.8 (40.1 to 49.5)
Statistical analysis
  • Secukinumab 300 mg s.c. vs Adalimumab 40 mg s.c. · Regression, Logistic · p = 0.2251 · Odds ratio (or): 1.18 · 95% CI 0.90 to 1.55Odds ratio, 95% confidence interval, and p-value are from a logistic regression model with treatment as a factor and baseline weight as a covariate
SecondaryChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI Score) at Week 52

The HAQ-DI assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, "are you able to..." perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Unit on a scale
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI Score) at Week 52
Unit on a scaleSecukinumab 300 mg s.c.Adalimumab 40 mg s.c.
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI Score) at Week 52-0.58 ± 0.027-0.56 ± 0.027
Statistical analysis
  • Secukinumab 300 mg s.c. vs Adalimumab 40 mg s.c. · Mixed Models Analysis · p = 0.5465 · Least squares (ls) mean change: -0.02 · 95% CI -0.10 to 0.05Mixed model repeated measures (MMRM) with treatment group, analysis visit as factors, weight/baseline score as covariates, treatment by analysis visit, baseline score by analysis visit as interation terms and unstructured covariance structure
SecondaryPercentage of Participants Who Achieved Resolution of Enthesitis at Week 52

Enthesitis refers to inflammation of entheses, the site where ligaments or tendons insert into the bones. Resolution was defined as the absence of recorded enthesitis; conducted by the study assessor.

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Resolution of Enthesitis at Week 52
Percentage of ParticipantsSecukinumab 300 mg s.c.Adalimumab 40 mg s.c.
Percentage of Participants Who Achieved Resolution of Enthesitis at Week 5260.5 (54.1 to 66.6)54.2 (48.2 to 60.2)
Statistical analysis
  • Secukinumab 300 mg s.c. vs Adalimumab 40 mg s.c. · Regression, Logistic · p = 0.1498 · Odds ratio (or): 1.30 · 95% CI 0.91 to 1.87Odds ratio, 95% confidence interval, and p-value are from a logistic regression model with treatment as a factor and baseline weight as a covariate

Adverse events

Collected over Treatment emergent adverse events were collected from first dose of study treatment until 12 Weeks (84 days) following the last administration of study treatment, an average of 68 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AIN457 300 mg1/426 (0.2%)37/426 (8.7%)226/426 (53.1%)
Adalimumab 40 mg0/427 (0%)36/427 (8.4%)236/427 (55.3%)
Total1/853 (0.1%)73/853 (8.6%)462/853 (54.2%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
EventAIN457 300 mgAdalimumab 40 mgTotal
PneumoniaInfections and infestations0/4263/4273/853
Acute myocardial infarctionCardiac disorders2/4260/4272/853
SyncopeNervous system disorders2/4260/4272/853
ProstatitisReproductive system and breast disorders0/4262/4272/853
AnaemiaBlood and lymphatic system disorders1/4260/4271/853
LymphadenopathyBlood and lymphatic system disorders1/4260/4271/853
Myocardial infarctionCardiac disorders1/4260/4271/853
PericarditisCardiac disorders1/4260/4271/853
Abdominal painGastrointestinal disorders1/4260/4271/853
Abdominal pain upperGastrointestinal disorders1/4260/4271/853
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAIN457 300 mgAdalimumab 40 mgTotal
NasopharyngitisInfections and infestations88/42684/427172/853
Upper respiratory tract infectionInfections and infestations42/42654/42796/853
Psoriatic arthropathyMusculoskeletal and connective tissue disorders34/42638/42772/853
DiarrhoeaGastrointestinal disorders32/42637/42769/853
HeadacheNervous system disorders36/42633/42769/853
PsoriasisSkin and subcutaneous tissue disorders33/42634/42767/853
ArthralgiaMusculoskeletal and connective tissue disorders29/42631/42760/853
Back painMusculoskeletal and connective tissue disorders17/42631/42748/853
Injection site reactionGeneral disorders4/42628/42732/853
HypertensionVascular disorders27/42624/42751/853

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Secukinumab 300 mg s.c.Adalimumab 40 mg s.c.Total
Mean48.5 ± 12.3849.5 ± 12.4449.0 ± 12.41
Sex: Female, Male
Sex: Female, Male(Participants)Secukinumab 300 mg s.c.Adalimumab 40 mg s.c.Total
Female218198416
Male208229437
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Secukinumab 300 mg s.c.Adalimumab 40 mg s.c.Total
Asian162036
American Indian or Alaska Native011
Black or African American325
White402391793
Unknown156
Other4812
08

Study locations

156 sites
  • Novartis Investigative Site
    Fountain Valley, California 92708, United States
  • Novartis Investigative Site
    Fullerton, California 92835, United States
  • Novartis Investigative Site
    La Mesa, California 91942, United States
  • Novartis Investigative Site
    Upland, California 91786, United States
  • Novartis Investigative Site
    Bowling Green, Kentucky 42101, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63117, United States
  • Novartis Investigative Site
    Lincoln, Nebraska 68516, United States
  • Novartis Investigative Site
    Omaha, Nebraska 68114, United States
  • Novartis Investigative Site
    Rochester, New York 14623, United States
  • Novartis Investigative Site
    Bethlehem, Pennsylvania 18015, United States
  • Novartis Investigative Site
    Duncansville, Pennsylvania 16635, United States
  • Novartis Investigative Site
    Arlington, Texas 76011, United States
  • Novartis Investigative Site
    Austin, Texas 78731, United States
  • Novartis Investigative Site
    Dallas, Texas 75231, United States
  • Novartis Investigative Site
    Mesquite, Texas 75150, United States
  • Novartis Investigative Site
    Burlington, Vermont 05401, United States
  • Novartis Investigative Site
    Seattle, Washington 98122, United States
  • Novartis Investigative Site
    Spokane, Washington 99204, United States
  • Novartis Investigative Site
    Glendale, Wisconsin 53217, United States
  • Novartis Investigative Site
    Kogarah, New South Wales 2217, Australia
  • Novartis Investigative Site
    Maroochydore, Queensland 4558, Australia
  • Novartis Investigative Site
    Hobart, Tasmania 7000, Australia
  • Novartis Investigative Site
    Malvern East, Victoria 3145, Australia
  • Novartis Investigative Site
    Pleven, 5800, Bulgaria
  • Novartis Investigative Site
    Plovdiv, 4000, Bulgaria
  • Novartis Investigative Site
    Plovdiv, 4002, Bulgaria
  • Novartis Investigative Site
    Sofia, 1413, Bulgaria
  • Novartis Investigative Site
    Sofia, 1606, Bulgaria
  • Novartis Investigative Site
    Victoria, British Columbia V8V 3M9, Canada
  • Novartis Investigative Site
    Winnipeg, Manitoba R3A 1M1, Canada
  • Novartis Investigative Site
    Trois-Rivieres, Quebec G8Z 1Y2, Canada
  • Novartis Investigative Site
    Bruntal, 792 01, Czechia
  • Novartis Investigative Site
    Praha 2, 128 50, Czechia
  • Novartis Investigative Site
    Praha 5, 150 06, Czechia
  • Novartis Investigative Site
    Uherske Hradiste, 686 01, Czechia
  • Novartis Investigative Site
    Zlin, 760 01, Czechia
  • Novartis Investigative Site
    Frederiksberg, DK-2000, Denmark
  • Novartis Investigative Site
    Tallinn, 10138, Estonia
  • Novartis Investigative Site
    Tallinn, 13419, Estonia
  • Novartis Investigative Site
    Tartu, 50406, Estonia
  • Novartis Investigative Site
    Hyvinkaa, 05800, Finland
  • Novartis Investigative Site
    Kuopio, 70100, Finland
  • Novartis Investigative Site
    Brive-la-Gaillarde, 19100, France
  • Novartis Investigative Site
    Cahors, 46000, France
  • Novartis Investigative Site
    Chambray les Tours, 37170, France
  • Novartis Investigative Site
    Le Mans, 72037, France
  • Novartis Investigative Site
    Orleans, 45100, France
  • Novartis Investigative Site
    Paris, 75010, France
  • Novartis Investigative Site
    Poitiers, 86021, France
  • Novartis Investigative Site
    Bad Doberan, 18209, Germany
  • Novartis Investigative Site
    Berlin, 10117, Germany
  • Novartis Investigative Site
    Berlin, 12161, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Berlin, 14059, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Erlangen, 91056, Germany
  • Novartis Investigative Site
    Hamburg, 22415, Germany
  • Novartis Investigative Site
    Herne, 44649, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Magdeburg, 39110, Germany
  • Novartis Investigative Site
    Osnabruck, 49074, Germany
  • Novartis Investigative Site
    Schwerin, 19055, Germany
  • Novartis Investigative Site
    Athens, 115 27, Greece
  • Novartis Investigative Site
    Athens, 12462, Greece
  • Novartis Investigative Site
    Thessaloniki, 54642, Greece
  • Novartis Investigative Site
    Budapest, 1023, Hungary
  • Novartis Investigative Site
    Budapest, 1027, Hungary
  • Novartis Investigative Site
    Budapest, 1062, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Gyor, 9023, Hungary
  • Novartis Investigative Site
    Kistarcsa, 2143, Hungary
  • Novartis Investigative Site
    Veszprem, 8200, Hungary
  • Novartis Investigative Site
    Reykjavik, 108, Iceland
  • Novartis Investigative Site
    Mumbai, Maharashtra 400 053, India
  • Novartis Investigative Site
    Nashik, Maharashtra 422 101, India
  • Novartis Investigative Site
    Secunderabad, Telangana 500003, India
  • Novartis Investigative Site
    New Delhi, 110029, India
  • Novartis Investigative Site
    Haifa, 3339419, Israel
  • Novartis Investigative Site
    Haifa, 343621, Israel
  • Novartis Investigative Site
    Haifa, 3525408, Israel
  • Novartis Investigative Site
    Kfar Saba, 4428164, Israel
  • Novartis Investigative Site
    Petach Tikva, 49100, Israel
  • Novartis Investigative Site
    Ramat Gan, 52621, Israel
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
  • Novartis Investigative Site
    Arenzano, GE 16011, Italy
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Verona, VR 37126, Italy
  • Novartis Investigative Site
    Bologna, 40138, Italy
  • Novartis Investigative Site
    Pisa, 56126, Italy
  • Novartis Investigative Site
    Torino, 10126, Italy
  • Novartis Investigative Site
    Seoul, Seocho Gu 06591, Korea, Republic of
  • Novartis Investigative Site
    Riga, LV-1005, Latvia
  • Novartis Investigative Site
    Valmiera, LV-4201, Latvia
  • Novartis Investigative Site
    Kaunas, LTU LT 50161, Lithuania
  • Novartis Investigative Site
    Klaipeda, LT-92288, Lithuania
  • Novartis Investigative Site
    Siauliai, LT-76231, Lithuania
  • Novartis Investigative Site
    Enschede, 7513 ER, Netherlands
  • Novartis Investigative Site
    Sneek, 8601 ZK, Netherlands
  • Novartis Investigative Site
    Dopiewo, 62 069, Poland
  • Novartis Investigative Site
    Szczecin, 71-252, Poland

Showing the first 100 of 156 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, Masmitja JG, Goupille P, Korotaeva T, Gottlieb AB, Martin R, Ding K, Pellet P, Mpofu S, Pricop L; EXCEED Study Group. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020 May 9;395(10235):1496-1505. doi: 10.1016/S0140-6736(20)30564-X. Erratum In: Lancet. 2020 May 30;395(10238):1694. doi: 10.1016/S0140-6736(20)31205-8. PubMed 32386593 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Dec 2019, 32 months.

Results were first posted in Jan 2021, 1 year after primary completion. A results delay was requested in May 2020.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 32 months is above that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2016
First posted
Apr 20, 2016
StartActual
Apr 3, 2017
Primary completionActual
Dec 30, 2019
CompletionActual
Dec 30, 2019
Results delay requested
May 19, 2020
Results first posted
Jan 27, 2021
Last update
Jan 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02745080
Responsible party
Sponsor
First posted
Apr 20, 2016
Start date
Apr 3, 2017
Primary completion
Dec 30, 2019
Completion
Dec 30, 2019
Results posted
Jan 27, 2021
Last update
Jan 27, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion